非小细胞肺癌患者SCC、ProGRP及CEA水平变化及临床意义  

Changes and clinical significance of SCC,ProGRP and CEA levels in patients with non⁃small cell lung cancer

作　　者：路颖慧 安美霞 朱雯怡 LU Yinghui;AN Meixia;ZHU Wenyi(Department of Thoracic Surgery,Beijing Friendship Hospital Affiliated to Capital Medical University,Beijing,China,100050)

机构地区：[1]首都医科大学附属北京友谊医院胸外科,北京100050

出　　处：《分子诊断与治疗杂志》2024年第5期967-970,共4页Journal of Molecular Diagnostics and Therapy

基　　金：北京市通州区科技计划项目(KJ2023CX014)。

摘　　要：目的探讨非小细胞肺癌(NSCLC)患者鳞状细胞癌相关抗原(SCC)、胃泌素释放肽前体(ProGRP)及癌胚抗原(CEA)水平变化及临床意义。方法回顾性分析2020年5月至2023年2月于首都医科大学附属北京友谊医院展开治疗的132例NSCLC患者的临床资料,设为A组;另抽取同期于本院治疗的71例肺良性病变患者,设为B组。比较两组患者SCC、ProGRP及CEA水平,分析不同临床特征NSCLC患者SCC、ProGRP及CEA水平,运用受试者工作特征(ROC)曲线分析SCC、ProGRP及CEA对NSCLC的诊断价值。结果A组患者血清SCC、ProGRP及CEA水平均高于B组患者,差异有统计学意义(P<0.05)。血清SCC、ProGRP、CEA及三者联合诊断NSC的AUC分别为0.691、0.815、0.822、0.832。不同病理类型、分化程度、临床分期及淋巴结转移的NSCLC患者血清SCC、ProGRP及CEA水平比较差异有统计学意义(P<0.05)。结论不同病理类型、分化程度、临床分期及淋巴结转移的NSCLC患者血清SCC、ProGRP及CEA存在差异,血清SCC、ProGRP及CEA均可有效辅助诊断NSCLC,且三者联合诊断能提高诊断效能。Objective To investigate the changes and clinical significance of squamous cell carci⁃noma⁃associated antigen(SCC),pro⁃gastrin releasing peptide(ProGRP)and carcinoembryonic antigen(CEA)levels in patients with non⁃small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on the clinical data of 132 patients with NSCLC who were treated at Beijing Friendship Hospital Af⁃filiated to Capital Medical University from May 2020 to February 2023.The patients were divided into group A,while 71 patients with benign pulmonary lesions were selected and placed in group B simultaneously.The levels of SCC,ProGRP and CEA were compared between the two groups,and further analysis was done on the levels of SCC,ProGRP and CEA in NSCLC patients with different clinical characteristics.The receiver op⁃erating characteristic(ROC)curves were used to evaluate the diagnostic value of SCC,ProGRP,and CEA in NSCLC.Results Serum SCC,ProGRP,and CEA levels in group A were higher than those in group B(P<0.05).The AUC values for serum SCC,ProGRP,CEA and their combination in diagnosing NSCLC were 0.691,0.815,0.822 and 0.832,respectively.There were statistically significant differences in serum SCC,ProGRP and CEA levels among NSCLC patients with different pathological types,different degrees of differ⁃entiation,various clinical stages,and with or without lymph node metastasis(P<0.05).Conclusion Patients with different pathological types,varying degrees of differentiation,diverse clinical stages,and presence or absence of lymph node metastasis exhibit varying levels of serum SCC,ProGRP and CEA.These biomarkers can significantly aid in the diagnosis of NSCLC,with a combination of all three leading to enhanced diagnostic accuracy.

关 键 词：非小细胞肺癌 鳞状细胞癌抗原 胃泌素释放前体 癌胚抗原 

分 类 号：R734.2[医药卫生—肿瘤]